Aflibercept May Be Effective for Resistant Exudative AMD Aflibercept May Be Effective for Resistant Exudative AMD

Aflibercept appears to improve outcomes in patients with exudative age-related macular degeneration (AMD) resistant to treatment with ranibizumab or bevacizumab, researchers from Norway report.Reuters Health Information
Source: Medscape Ophthalmology Headlines - Category: Opthalmology Tags: Ophthalmology News Source Type: news

Related Links:

Publication date: August 2019Source: Nutrition, Metabolism and Cardiovascular Diseases, Volume 29, Issue 8Author(s): Monica Dinu, Giuditta Pagliai, Alessandro Casini, Francesco Sofi
Source: Nutrition, Metabolism and Cardiovascular Diseases - Category: Nutrition Source Type: research
Conclusion: The expression of sFRP1 accelerates the aging process in mouse eyes and future studies are warranted to elucidate the underlying mechanisms. PMID: 31318361 [PubMed]
Source: Journal of Ophthalmology - Category: Opthalmology Tags: J Ophthalmol Source Type: research
Conclusions: Inhibition of ROCK signaling by using 10 μM Y27632 promoted RPE cell motility during wound healing by reducing RPE cell adhesion strength. PMID: 31316826 [PubMed]
Source: Journal of Ophthalmology - Category: Opthalmology Tags: J Ophthalmol Source Type: research
Authors: Nemcansky J, Stepanov A, Koubek M, Veith M, Klimesova YM, Studnicka J Abstract Purpose: To present a cohort of treatment-naive patients with the neovascular form of age-related macular degeneration (nAMD) treated with aflibercept in a fixed regimen and evaluate the treatment response of three types of choroidal neovascular membrane (CNV)-occult (Type 1), classic (Type 2), and minimally classic (Type 4). Methods: This was a multicentre, prospective, observational consecutive case series study. Patients diagnosed with three types of CNV of nAMD were treated in a fixed regimen (3 injections every 4&thinsp...
Source: Journal of Ophthalmology - Category: Opthalmology Tags: J Ophthalmol Source Type: research
Conclusion: Further prospective, randomized studies of ziv-aflibercept are needed, particularly in eyes with nAMD. PMID: 31314638 [PubMed - as supplied by publisher]
Source: Seminars in Ophthalmology - Category: Opthalmology Tags: Semin Ophthalmol Source Type: research
New age-related macular degeneration (AMD) develops in about a quarter of fellow eyes to those treated for neovascular AMD with intravitreal anti-VEGF agents, according to a post hoc analysis of the VIEW 1 and VIEW 2 studies.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Authors: Costagliola C, Morescalchi F, Duse S, Romano D, Mazza G, Parmeggiani F, Bartollino S, Semeraro F Abstract Introduction: Intravitreal anti-VEGF is the most effective therapy for wet AMD, although systemic effects on the endothelium cannot be excluded. Areas covered: The purpose of this review was to evaluate risk of thromboembolic events associated with intravitreal anti-VEGF. Expert opinion: Current data are insufficient to confirm the safety of these compounds, due to the paucity of specific studies. Thus, pharmacovigilance for all anti-VEGF should be improved to verify the true role of anti-VEGF in the o...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
Abstract The pathophysiological mechanisms for dry and wet age-related macular degeneration (AMD) involve oxidative stress and increased VEGF release and expression. An ideal drug candidate for both types of AMD is the one which offers significant protection to the retinal cells from oxidative stress and inhibit VEGF release. Curcumin is one such natural product which provides numerous beneficial effects including antioxidant, anti-inflammatory, and anti-VEGF activities and has the potential for the treatment of both types of AMD. The bioavailability of curcumin is negligible due to its poor aqueous solubility. Th...
Source: AAPS PharmSciTech - Category: Drugs & Pharmacology Authors: Tags: AAPS PharmSciTech Source Type: research
Inflammation underpins and contributes to the pathogenesis of many retinal degenerative diseases. The recruitment and activation of both resident microglia and recruited macrophages, as well as the production of cytokines, are key contributing factors for progressive cell death in these diseases. In particular, the interleukin 1 (IL-1) family consisting of both pro- and anti-inflammatory cytokines has been shown to be pivotal in the mediation of innate immunity and contribute directly to a number of retinal degenerations, including Age-Related Macular Degeneration (AMD), diabetic retinopathy, retinitis pigmentosa, glaucoma...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
ConclusionThe data regarding nutritional supplements in preventing AMD progression are inconclusive, and therefore recommendations should be based on risk factors and demographic data.
Source: International Ophthalmology - Category: Opthalmology Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Avastin | Lucentis | Opthalmology | Ranibizumab Injection